Pay in 4 interest-free payments of $5.80 Learn more
Ships within 48 hours · Estimated delivery Oct 14 - Oct 19
Different patient populations, different enrollment criteria, different sites, and different measurement protocols all introduce variability that makes direct numerical comparison imprecise
Triple-hormone-receptor agonist Retatrutide for obesity: Phase 2 trial (48-week study, up to 24% weight loss) American Diabetes Association (2023) ADA Press Release: Novel agent Retatrutide results in substantial weight reduction (83rd Scientific Sessions, Phase 2 data) ADA Meeting News (2023) Phase 2 trial results: benefits of Retatrutide in obesity, type 2 diabetes, NASH (83rd ADA Scientific Sessions coverage) ClinicalTrials.gov Study of Retatrutide (LY3437943) in adults with obesity (NCT04881760
Additional Metabolic Pathways Beyond beta-3 receptor activation, research suggests AOD-9604 may influence additional adipose-specific pathways
Unlike many peptidergic agents that require carriers for stability and bioavailability, BPC-157 functions effectively when administered alone, making it practical for various therapeutic applications
Int J Mol Sci 2022;23:4259
